|
|
Blood, 1 January 2008, Vol. 111, No. 1, pp. 71-76.
Prepublished online as a Blood First Edition Paper on September 21, 2007; DOI 10.1182/blood-2007-02-073544.
 Previous Article | Next Article 
Submitted February 26, 2007
Accepted August 20, 2007
Fertility in male patients with advanced Hodgkin Lymphoma treated with BEACOPP: a report of the German Hodgkin Study Group (GHSG)
Michal Sieniawski*, Thorsten Reineke, Lucia Nogova, Andreas Josting, Beate Pfistner, Volker Diehl, and Andreas Engert
Department I Internal Medicine, University Hospital Cologne, Cologne, Germany
German Hodgkin Study Group, University Hospital Cologne, Cologne, Germany
* Corresponding author; email: michal.sieniawski{at}ncl.ac.uk.
To date, there is little information on the impact of more aggressive treatment regimen such as BEACOPP (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone) on the fertility of male patients with Hodgkin Lymphoma (HL). We evaluated the impact of BEACOPP regimen on fertility status in 38 male patients with advanced stage HL enrolled into trials of the German Hodgkin Study Group (GHSG). Before treatment, 6 (23%) patients had normozoospermia and 20 (77%) patients had dysspermia. After treatment, 34 (89%) patients had azoospermia, 4 (11%) other dysspermia and no patient had normozoospermia. There was no difference in azoospermia rate between patients treated with BEACOPP baseline and those given BEACOPP escalated (93% vs. 87%, respectively; p=1.0000). After treatment most of patients (93%) had abnormal values of follicle-stimulating hormone whereas the number of patients with abnormal levels of testosterone and luteinising hormone was less pronounced – 57% and 21%, respectively. In univariate analysis, none of the evaluated risk factors (i.e. age, clinical stage, elevated erythrocyte sedimentation rate, B symptoms, large mediastinal mass, extranodal disease and  3 lymph nodes) was statistically significant. Male HL patients are at high risk of infertility after treatment with BEACOPP.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
A. Engert, V. Diehl, J. Franklin, A. Lohri, B. Dorken, W.-D. Ludwig, P. Koch, M. Hanel, M. Pfreundschuh, M. Wilhelm, et al.
Escalated-Dose BEACOPP in the Treatment of Patients With Advanced-Stage Hodgkin's Lymphoma: 10 Years of Follow-Up of the GHSG HD9 Study
J. Clin. Oncol.,
September 20, 2009;
27(27):
4548 - 4554.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Avigdor, S. Bulvik, I. Levi, E. J. Dann, N. Shemtov, G. Perez-Avraham, A. Shimoni, A. Nagler, I. Ben-Bassat, and A. Polliack
Two cycles of escalated BEACOPP followed by four cycles of ABVD utilizing early-interim PET/CT scan is an effective regimen for advanced high-risk Hodgkin's lymphoma
Ann. Onc.,
July 16, 2009;
(2009)
mdp271v1.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Brusamolino, A. Bacigalupo, G. Barosi, G. Biti, P. G. Gobbi, A. Levis, M. Marchetti, A. Santoro, P. L. Zinzani, and S. Tura
Classical Hodgkin's lymphoma in adults: guidelines of the Italian Society of Hematology, the Italian Society of Experimental Hematology, and the Italian Group for Bone Marrow Transplantation on initial work-up, management, and follow-up
Haematologica,
April 1, 2009;
94(4):
550 - 565.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
